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Abstract
Atrial high rate episodes (AHREs), also termed, subclinical atrial tachyarrhythmias or subclinical atrial fibrillation (AF) are 
an important cardiovascular condition. Advancement in implantable cardiac devices such as pacemakers or internal cardiac 
defibrillators has enabled the continuous assessment of atrial tachyarrhythmias in patients with an atrial lead. Patients with 
device-detected AHREs are at an elevated risk of stroke and may have unmet anticoagulation needs. While the benefits of 
oral anticoagulation for stroke prevention in patients with clinical AF are well recognised, it is not known whether the same 
risk–benefit ratio exists for anticoagulation therapy in patients with AHREs. The occurrence and significance of AHRE 
are increasingly acknowledged but these events are still not often acted upon in patients presenting with stroke and TIA. 
Additionally, patients with AHRE show a significant risk for major adverse cardiovascular events (MACE) including acute 
heart failure, myocardial infarction, cardiovascular hospitalisation, ventricular tachycardia/fibrillation, which is dependent 
on AHRE burden. In this review, we present an overview of this relatively new entity, its associated thromboembolic risk 
and its management implications.
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Introduction
Atrial high rate episodes (AHREs), also termed, subclini-
cal atrial tachyarrhythmias or subclinical atrial fibrillation 
(AF) are an important cardiovascular condition. AHRE 
is defined as an episode of fast heart rate, i.e. more than 
180 beats per minute (bpm) lasting at least 5 min as per 
the European Society of Cardiology (ESC) 2016 guide-
lines [1]. Cardiovascular implantable electronic devices 
(CIEDs), such as permanent pacemakers (PPM), implant-
able cardioverter defibrillators (ICDs), cardiac resynchro-
nisation therapy (CRT) devices [pacemakers (CRT-P) 
and defibrillators (CRT-D)], are being used increasingly 
throughout the world. Such devices with an atrial lead 
can detect episodes of atrial arrhythmias, regardless of 
the presence of symptoms. This relatively new entity is 
distinct from detection of AF via portable ECG monitor-
ing and new devices and applications capable of recording 
ECG such as Apple Watch, which requires consideration 
on its own merit.
Patients with CIEDs represent a unique population with 
multiple comorbidities predisposing to atrial arrhythmias. 
Most of these AHREs are asymptomatic and sensed in 
asymptomatic individuals at a routine pacing clinic follow-
up. A recent study showed that more than half of patients 
with ICD for primary prophylaxis with sinus rhythm at 
baseline developed new AF or ventricular arrhythmia after 
6 years [2]. The onset of these arrhythmias was found to 
be independent prognostic factors for increased mortality 
in this group of patients [2].
The incidence of AHRE in patients without a his-
tory of AF is approximately 25% after 1 year and 35% 
after 2 years of follow-up [3–5]. AHRE differ from AF 
in the manner of documentation, i.e. AF is established 
on an electrocardiogram (ECG), whereas AHREs are 
solely recorded on a CIED read-out [1]. Several factors 
have been identified to be associated with AHRE onset. 
These include, age, prior AF, white cell count and high 
C-reactive protein (CRP) [6]. Furthermore, similarities are 
being drawn between paroxysmal AF (PAF) and AHREs. 
PAF, as opposed to permanent AF, is transient, infrequent 
and often asymptomatic. There is evidence to suggest that 
asymptomatic PAF episodes occur with much greater fre-
quency than symptomatic PAF [7]. Thus, patients with 
CIEDs present a unique opportunity to screen for and 
unmask silent AF episodes.
Irrespective of AF diagnosis, patients with device-
detected AHREs are at an elevated risk of stroke and may 
have unmet anticoagulation needs [8]. The incidence of 
AHRE detected by CIED can reach 50% but less than 25% 
of these patients are treated with an oral anticoagulant 
[9]. While the benefits of oral anticoagulation for stroke 
prevention in patients with clinical AF are well recog-
nised, it is not known whether the same risk–benefit ratio 
exists for anticoagulation therapy in patients with AHREs 
[8]. Some studies do suggest that AHRE and AF differ 
regarding thromboembolism risk. In AHRE patients, the 
thromboembolic risk appears to be lower than in clinical 
AF [4, 10–13].
The pathophysiology behind increased thromboembolic 
risk in patients with AHRE has not yet been clearly estab-
lished. Atrial abnormalities that predispose to development 
of atrial arrhythmias increase the risk of thromboembolism, 
irrespective of the presence of the arrhythmia [14]. This 
hypothesis is supported by the notion that the majority of 
strokes in patients with CIED-detected AHRE do not occur 
within 30 days of the last episode of AHRE [15, 16]. Thus, 
a relation between severity of atrial cardiomyopathy and 
AHRE burden is yet to be recognised.
Are AHREs a precursor to atrial fibrillation?
Advances in implantable cardiac devices, such as PPM and 
ICD, allow long-term continuous heart rhythm monitoring 
and have enabled the continuous assessment of atrial tach-
yarrhythmias in patients with an atrial lead [17, 18]. How-
ever, each CIED manufacturer uses a different definition for 
AHRE which makes it difficult to standardise the captured 
data. There is a tendency in clinical practice to assume that 
AHREs detected by CIEDs are equivalent to having AF. The 
CIEDs’ AHRE algorithm has a high sensitivity for detection 
of AF, ranging from 94 to 100% [17, 19, 20]. Nonetheless, 
utilisation of device-detected AHREs to diagnose AF is not 
perfect due to false negatives, especially when the duration 
of AHRE is brief, i.e. less than 30 s [21].
The researchers working on the Asymptomatic Atrial 
Fibrillation and Stroke Evaluation in Pacemaker Patients 
and the Atrial Fibrillation Reduction Atrial Pacing Trial 
(ASSERT) independently reviewed nearly 6000 AHREs 
(defined in their study as episodes of heart rate more than 
190 beats per minute for more than 6 min) and discovered 
that 17.3% were false positives [22]. However, the rate of 
false positives was reduced to 3.3% when using a longer 
threshold of 6 h for AHRE duration suggesting that longer 
the duration of AHRE, the lower the number of false-pos-
itive detections [22]. Possible reasons for false positives 
include oversensing of the atrial lead, runs of pacemaker 
lead-mediated arrhythmia, premature atrial complexes, far-
field R-wave sensing, or other external interference.
Irrespective of the above, the occurrence and signifi-
cance of AHRE are increasingly acknowledged but these 
events are still not often acted upon in patients presenting 
with stroke and TIA. An analysis of the Atrial Fibrillation 
Follow-up Investigation of Rhythm Management (AFFIRM) 
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study discovered that 12% of patients were asymptomatic 
at baseline [23]. These patients had a lower incidence of 
serious heart disease but more strokes [23]. 5% of patients 
presenting with an acute stroke have previously undetected 
AF on admission. Subsequent intermittent 12 lead ECG or 
Holter monitoring has identified higher incidences of undi-
agnosed AF in stroke survivors [24, 25]. The early detection 
of AHREs is thus clinically relevant considering that they 
have been shown to be associated with an elevated risk of 
thromboembolic events and death, such as 1.8%/year in the 
IMPACT trial, a multicentre randomised study of anticoagu-
lant guided by remote rhythm monitoring in patients with 
implantable cardioverter–defibrillator and CRT-D devices 
[4, 8, 15, 26–28].
Most of the data on AHRE have been obtained from 
patients with cardiac devices in situ. Many of these patients 
have sinus node disease and/or ventricular pacing which 
are associated with a higher incidence of AF. Thus, the 
prevalence of AHRE may be lower in the general popula-
tion [29, 30]. A growing body of clinical data support the 
hypothesis that AHREs are associated with an elevated risk 
of stroke [8]. A recent meta-analysis by Uittenbogaart et al. 
showed that patients with an AHRE burden over 6 min had 
an increased risk of thromboembolic event when compared 
with patients without AHRE but this risk did not increase for 
an AHRE burden over 6 h (hazard ratio (HR) 1.82 vs 1.78) 
[31]. In a second meta-analysis, they discovered that only 
patients with AHRE burden over 24 h had an increased risk 
for stroke (HR 3.2, 95% confidence interval (CI) 1.75–5.86) 
while patients with an AHRE burden < 24 h did not [31].
Benezet–Mazuecos et  al. prospectively analysed the 
incidence of AHRE (defined as heart rate ≥ 225 bpm and 
lasting > 5 min) in 109 patients and the presence of silent 
ischaemic brain lesion on computed tomography (CT) scan 
[32]. Multivariate analysis demonstrated that AHRE was an 
independent predictor of silent ischaemic stroke (HR 9.76, 
95% CI 1.76–54.07; p < 0.05) [32].
An ancillary study of the Mode Selection Trial (MOST) 
discovered that patients (n = 312) with sinus node dys-
function who experienced AHRE (defined as atrial 
rate > 220 bpm for 10 consecutive beats) were more likely 
to have adverse clinical outcomes, including 6 times as likely 
to develop AF and twice as likely to have a stroke or die than 
patients without AHRE (20.6% vs 10.5%; HR 2.79, 95% CI 
1.51–5.15, p = 0.001; no annual rates reported) [19]. The 
study was, however, limited by its retrospective design, small 
sample size and that 80% of enrolled patients had a previous 
history of supraventricular arrhythmia.
The TRENDS trial (A Prospective Study of the Clini-
cal Significance of Atrial Arrhythmias Detected by 
Implanted Device Diagnostics) was a prospective, multi-
centre observational study looking at 2486 patients with a 
CIED and  CHADS2 [congestive heart failure, hypertension, 
age ≥ 75 years, diabetes mellitus and prior stroke (doubled)] 
score ≥ 1 showed that the annual thromboembolic risk dou-
bled in patients with a high atrial tachycardia (AT)/AF 
burden (defined as AHRE of ≥ 5.5 h), compared to patients 
with zero or low burden, i.e. < 5.5 h per day (2.4% vs 1.1% 
per year; HR 2.20, 95% CI 0.96–5.05, p = 0.06) [10]. The 
AHRE itself was defined as > 175 bpm lasting at least 20 s. 
The risk remained elevated even after adjustment for other 
risk factors. This study did include patients with prior his-
tory of AF, although incidental AHRE was noted in 45% of 
1988 patients without a documented history of prior AF. 
Similarly, Turakhia et al. showed that patients who suffered 
a stroke had more often AHRE lasting ≥ 5.5 h in the 30 days 
preceding the stroke compared with a control period of days 
91 to 120 prior to the stroke in the same patients (HR 4.2, 
95% CI 1.5–13.4) [33].
More recently, the Asymptomatic Atrial Fibrillation and 
Stroke Evaluation in Pacemaker Patients and the Atrial 
Fibrillation Reduction Atrial Pacing Trial (ASSERT) 
was designed as a prospective, multicentre, observa-
tional study to assess if AHREs can be associated with 
an increased risk of ischaemic stroke in patients with no 
prior history of AF [4]. The study followed 2580 patients 
with recently implanted pacemaker or ICD for a mean of 
2.5 years and found that the presence of AHRE (defined as 
AHRE > 190 bpm lasting > 6 min) was predictive of stroke 
or systemic embolism even after adjustment for predictors of 
stroke (HR 2.50; 95% CI 1.28–4.89; p = 0.008) [4].
The subanalysis of the ASSERT study looking at the 
duration of AHRE and thromboembolic risk using time-
dependent Cox regression model showed that thromboem-
bolic risk only increased in patients with AHRE lasting more 
than 24 h (HR 3.24, 95% CI 1.51–6.95, p = 0.003) compared 
to patients without AHRE [34]. For AHRE lasting < 24 h, 
the thromboembolic risk appeared to be similar to patients 
without AHRE [34]. Furthermore, the number of AHRE did 
not affect thromboembolic risk [4]. Interestingly, the annu-
alised thromboembolic event rate was found to be equal to 
2.1% in the subgroup with  CHADS2 score > 2, which was 
similar to TRENDS (2.4%). This is, however, still below the 
4–4.5% annual rate expected in clinical AF patients with a 
similar risk profile [35].
Data from TRENDS and ASSERT are further supported 
by multiple smaller prospective trials which assessed the 
relationship between AHREs and thromboembolic events in 
patients with CIEDs. Capucci et al. looked at 725 patients 
with dual chamber PPM and discovered that AHRE last-
ing < 24 h did not significantly increase embolic risk, while 
episodes > 24 h did (odds ratio 3.1) [36]. Botto et al. in a 
separate study looked at 562 patients with dual-chamber 
PPM and followed them for 1 year post-implantation [37]. 
They stratified patients using a combination of AHRE bur-
den and  CHADS2 score [37]. They discovered that separate 
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populations with different stroke risk emerged [37]. Patients 
with AHRE > 5 min and  CHADS2 score of ≥ 2 and cumula-
tive AHRE > 24 h with  CHADS2 score > 1 had an annualised 
thromboembolic event rate of as high as 5% [37].
There are several other studies that have established 
a clear association between AHRE and increased risk of 
stroke as summarised in Table 1 [29, 30, 38, 39]. How-
ever, apart from the ASSERT trial, all other studies have 
included patients with a history of AF. Hence, the sole 
effect of AHRE on thromboembolic event cannot be reli-
ably assessed. Additionally, half of these trials have included 
small sample sizes. Furthermore, there have been differences 
among the trials in the characteristics of the patient popula-
tions, use of anticoagulation, the pacing algorithm used and 
the atrial lead positions which will lead to statistical limita-
tions and the inferences from these studies. Low frequency 
of thromboembolic events leaves an extensive room for sta-
tistical error associated with the estimation of thromboem-
bolic event rates or risk related to predictors of such events.
Studies have included patients with various devices 
implanted, each with their own detection algorithm, which 
could translate to differences. AHREs were predominantly 
confirmed by device algorithms with very high sensitiv-
ity (100%), specificity (97%) and positive predictive value 
(100%) [36]. This together with the long duration of AHREs 
detected (usually in hours) and included in most studies such 
as ASSERT suggest that chances of missing or detection 
of false-positive AHRE were remote. Consequently, infor-
mation on false-positive AHREs identified in these various 
studies has not been provided by the researchers. Further-
more, additional steps to confirm AHRE by reviewing of 
intracardiac electrograms were limited to a few studies. In 
some studies, this was performed by cardiac electrophysiol-
ogy experts whereas in others it was done by clinicians with 
no specification of their expertise levels.
Although an increased risk of thromboembolism and 
AHRE has been shown in multiple studies, a clear temporal 
relationship between AHRE and subsequent stroke risk has 
not yet been identified. In a subgroup analysis of TRENDS, 
approximately 50% of patients who suffered a stroke or TIA 
had an AHRE episode recorded prior to the event, 25% of 
stroke patients had an AHRE within a month of the event 
and only 15% were associated with an AHRE during the 
event [16]. These findings are similar to ASSERT data 
where only half of the patients sustained an AHRE prior to 
their thromboembolic stroke event, 12% within 30 days and 
2% during the stroke event [40]. It is plausible that instead 
of causing embolic events, AHREs are simply a marker for 
thromboembolic risk [40]. Besides, studies that had patients 
with prior AF included or considered required recent pres-
ence of AF or two AF episodes documented on a 12 lead 
ECG [36]. Thus, the AF burden in these patients would be 
higher as oppose to patients with no previous history of AF.
Of note, the risk due to AHRE may extend beyond 
increased risk of stroke. A study looking at 224 patients with 
no history of AF who underwent dual-chamber PPM discov-
ered that AHREs were associated with a significant increase 
in cardiovascular mortality (HR 2.80; 95% CI 1.24–6.31; 
p = 0.013) and stroke mortality (HR 1.79, 95% CI 0.98–3.26; 
p = 0.059) [41]. A recent study by Pastori et al. showed 
that patients with AHRE show a significant risk for major 
adverse cardiovascular events (MACE) including acute heart 
Table 1  Overview of AHRE trials regarding thromboembolism risk
AT atrial tachycardia, bpm beats per minute, RR relative risk; TE thromboembolism, h hour(s), min minute(s), s second(s)
a Combined endpoint of death and non-fatal stroke
Trial n Prior AF (%) Mean
CHADS2 score
Definition of AHRE AHRE + annual
TE (%)
AHRE − annual 
TE (%)
RR for TE p
atrial rate Duration
ASSERT [4] 2580 0 2.2  > 190 bpm  > 6 min 1.7 0.7 2.5 0.007
AT500 [36] 725 100 – AT/AF  > 24 h – – 3.1 0.044
Benezet-Mazuecos 
[32]
109 31 2.3  ≥ 225 bpm  ≥ 5 min – – 3.04  < 0.05
ClinicalService [27] 3907 21 2 - - 0.21 – - –
IMPACT [15] 227 17.6 2.5  ≥ 220 bpm  ≥ 5 min 3.1 2.3 − 35.3 0.251
Kawakami et al. [48] 343 24 2.3  ≥ 175 bpm  > 6 min 8.48 2.8 2.87 0.03
Li et al. [49] 594 0 3.2  ≥ 175 bpm  ≥ 5 min 1.85 1.14 1.31 0.582
Miyazawa et al. [50] 856 24.8 1.9  ≥ 175 bpm  ≥ 5 min 2.6 0.9 3.4a 0.01
MOST [19] 312 60 –  > 220 bpm  > 5 min – – 2.8a 0.001
PANORAMA [27] 3556 25 2  > 175 bpm  ≥ 20 s 0.28 – – –
SOS AF Project [27] 10,016 24 2  > 175 bpm  ≥ 20 s 1.28 0.72 2.05 0.005
TRENDS [10] 2486 20 2.2  > 175 bpm  ≥ 5.5 h 2.4 1.1 2.2 0.06
Turakhia et al. [33] 9850 41 3.2 AT/AF  ≥ 5.5 h – – 4.2  < 0.05
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failure, myocardial infarction, cardiovascular hospitalisation, 
ventricular tachycardia/fibrillation, which is dependent on 
AHRE burden [28].
Management of AHRE
Anticoagulation therapy is well established for the manage-
ment of stroke prophylaxis in patients with AF diagnosed by 
standard ECG. At present, the management of patients with 
device-detected AHRE remains controversial with uncer-
tainties surrounding false positives, duration of the longest 
AHRE episode, the cumulative duration and the individual 
stroke risk [9]. There is at present limited evidence from 
randomised clinical studies to inform management of sub-
clinical AF detected by AHRE interrogation through cardiac 
devices. Thus, selecting the most appropriate anti-throm-
botic therapy for patients with AHRE is one of the evidence 
gaps highlighted by the ESC guidelines on the management 
of AF [1].
Recently, 46 European device-implanting centres took 
part in a European Heart Rhythm Association survey to cap-
ture the current clinical practice [42]. 53% of cardiologists 
recommended anticoagulation when  CHA2DS2-VASc (con-
gestive heart failure, hypertension, age ≥ 75 years (doubled), 
diabetes mellitus, prior stroke (doubled), vascular disease, 
age ≥ 65 years and sex) score was 2–3 as opposed to 70% 
when  CHA2DS2-VASc score was 4 when presented with a 
clinical scenario where a single AHRE was detected last-
ing more than 6 min [42]. This accurately represents the 
heterogeneity in the clinical attitude towards management 
of AHRE [42]. Overall, the inclination was shown towards 
favouring anticoagulation in those patients with a higher 
 CHA2DS2-VASc score, multiple AHRE and longer dura-
tion of episodes [42].
Taking into account the current literature and while await-
ing outcome from ongoing randomised clinical trials com-
paring oral anticoagulation vs no anticoagulation in patients 
with device-detected AHRE such as ARTESiA (Apixaban 
vs Aspirin; n = 4000) and NOAH (Edoxaban vs Aspirin; 
n = 3400) with a primary endpoint composite of stroke, 
systemic embolism and cardiovascular death, the European 
Society of Cardiology has provided some recommendations 
with regard to the management of AHRE patients [1, 43, 
44].
The ESC 2016 guidelines recommend that in patients 
with detectable AHRE on implanted device should be 
assessed for history of previous ischaemic stroke or episode 
of AF [1]. If there is no evidence of such, AF should be 
thoroughly looked for using 12-lead ECG, rhythm strip or 
prolonged review of intracardiac electrograms [1]. If still no 
clinical AF, then patients with AHRE ≥ 24 h (high burden) 
and  CHA2DS2-VASc score of ≥ 2 for men and ≥ 3 for women 
should be anticoagulated [1]. Figure 1 represents a flowchart 
to summarise this recommendation.
Conclusion
AHREs are a common finding in patients with cardiac 
implanted devices without a history of AF. Following 
advances in cardiac monitoring, it is likely that AHRE will 
be increasingly reported in the future. AHREs are often 
considered equivalent to clinical paroxysmal AF. This view 
has been supported by previous studies demonstrating that 
AHREs have a high correlation with clinically documented 
AF [45].
It is now increasingly recognised that AHRE are associ-
ated with an increased thromboembolic risk, although lower 
than in clinical AF, dependent on the duration of the AHRE. 
Thus, the initiation of anticoagulation therapy is naturally 
tempting. The lack of concrete evidence for a temporal rela-
tionship between AHRE and stroke, lack of specific rec-
ommendations regarding use of CIEDs for diagnosis and 
management of AF, sparse evidence on the critical threshold 
for duration/number of AHRE burden and absence of stud-
ies demonstrating benefit of oral anticoagulation therapy in 
patients with device-detected AHRE reflects the variation in 
individual clinical practice.
The pathological and prognostic significance of AHRE 
has not been completely established. Despite the overall 
stroke rate in patients with AHREs appears to be less than 
that found with clinical AF, it is still imperative to identify 
a certain high-risk population who deserve anticoagula-
tion therapy, provided that embolic risk exceeds the risk of 
serious bleeding. Thus by combining AHRE burden with 
 CHA2DS2-VASc score and HAS-BLED score, one can 
individualise oral anticoagulation therapy for appropriate 
patients at high risk of stroke [37]. Based on limited avail-
able evidence, it appears reasonable to commence antico-
agulation in patients without AF and at least one episode 
of AHRE lasting ≥ 24 h and a  CHA2DS2-VASc score of ≥ 2 
for men and ≥ 3 for women as per the ESC 2016 guidelines, 
while awaiting definite answers from ongoing randomised 
clinical trials, ARTESiA and NOAH. Patients with shorter 
AHRE (AHRE < 24 h) should at present be frequently moni-
tored with remote monitoring for propagation to high burden 
AHRE and/or development of AF until more definitive evi-
dence comes to light [46].
There is an unmet need for high quality evidence. 
Future studies must consider a standardised definition of 
AHRE, as past studies have used various definitions. They 
should also consider how CIEDs algorithms operate and 
detect AHREs as a recent study found significant varia-
tion in diagnostic accuracy among devices and according 
to the level of operator expertise [47]. The use of oral 
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anticoagulation therapy for stroke prophylaxis in patients 
with AHRE should also be evaluated including cost effec-
tiveness. Future studies should also address the impact 
of treatment on patient’s quality of life. Such studies will 
improve the existing variable and poorly informed evi-
dence and help inform shared decision-making, clinical 
guideline development and health policy.
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